{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T09:48:23Z","timestamp":1772185703440,"version":"3.50.1"},"reference-count":30,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2013,2,4]],"date-time":"2013-02-04T00:00:00Z","timestamp":1359936000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0054279","type":"journal-article","created":{"date-parts":[[2013,2,4]],"date-time":"2013-02-04T16:58:29Z","timestamp":1359997109000},"page":"e54279","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":32,"title":["52-Week Efficacy and Safety of Telbivudine with Conditional Tenofovir Intensification at Week 24 in HBeAg-Positive Chronic Hepatitis B"],"prefix":"10.1371","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct00651209","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Teerha","family":"Piratvisuth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piyawat","family":"Komolmit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tawesak","family":"Tanwandee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wattana","family":"Sukeepaisarnjaroen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry L. Y.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e1rio G.","family":"Pess\u00f4a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Fassio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzane K.","family":"Ono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Bessone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Daruich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Zeuzem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugo","family":"Cheinquer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rashidkhan","family":"Pathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhong","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aldo","family":"Trylesinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2013,2,4]]},"reference":[{"key":"ref1","first-page":"3","article-title":"Epidemiology and natural history of hepatitis B. Semin Liver Dis","volume":"25","author":"BJ McMahon","year":"2005"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1177\/135965350701200816","article-title":"Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease","volume":"12","author":"MF Yuen","year":"2007","journal-title":"Antivir Ther"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/hep.22841","article-title":"Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy","volume":"49","author":"DJ Tenney","year":"2009","journal-title":"Hepatology"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1128\/AAC.48.9.3498-3507.2004","article-title":"Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine","volume":"48","author":"DJ Tenney","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"ref5","first-page":"486","article-title":"2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology","volume":"136","author":"YF Liaw","year":"2009"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1177\/135965350501000507","article-title":"Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV","volume":"10","author":"H Yang","year":"2005","journal-title":"Antivir Ther"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1523-1755.2004.00866.x","article-title":"Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies","volume":"66","author":"H Izzedine","year":"2004","journal-title":"Kidney Int"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"745","DOI":"10.7326\/0003-4819-147-11-200712040-00183","article-title":"Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial","volume":"147","author":"HL Chan","year":"2007","journal-title":"Ann Intern Med"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/hep.22658","article-title":"Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir","volume":"49","author":"N Leung","year":"2009","journal-title":"Hepatology"},{"key":"ref10","first-page":"2442","article-title":"Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med","volume":"359","author":"P Marcellin","year":"2008"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1086\/655681","article-title":"Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients","volume":"51","author":"RD Cooper","year":"2010","journal-title":"Clin Infect Dis"},{"key":"ref12","first-page":"S72","article-title":"Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology","volume":"49","author":"CJ Chen","year":"2009"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1053\/jhep.2003.50208","article-title":"Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature","volume":"37","author":"H Mommeja-Marin","year":"2003","journal-title":"Hepatology"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1053\/jhep.2001.27563","article-title":"Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy","volume":"34","author":"MF Yuen","year":"2001","journal-title":"Hepatology"},{"key":"ref15","first-page":"2576","article-title":"Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med","volume":"357","author":"CL Lai","year":"2007"},{"key":"ref16","first-page":"890","article-title":"Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol","volume":"5","author":"EB Keeffe","year":"2007"},{"key":"ref17","first-page":"227","article-title":"EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol","volume":"50","author":"Liver European Association For The Study Of The","year":"2009"},{"key":"ref18","first-page":"507","article-title":"Chronic hepatitis B. Hepatology","volume":"45","author":"AS Lok","year":"2007"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"DW Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1053\/ajkd.2002.30944","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Part 5. Evaluation of laboratory measurements for clinical assessment of kidney disease","volume":"39","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group","volume":"130","author":"AS Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"ref22","first-page":"342","article-title":"[The degree of HBV suppression with 24 week telbivudine- or lamivudine-treatment in hepatitis B patients predicts the efficacy of the treatment at week 52]","volume":"15","author":"JD Jia","year":"2007","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"ref23","first-page":"11","article-title":"Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol","volume":"51","author":"S Zeuzem","year":"2009"},{"key":"ref24","first-page":"S166","article-title":"Monitoring during and after antiviral therapy for hepatitis B. Hepatology","volume":"49","author":"KL Andersson","year":"2009"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0140-6736(09)60207-5","article-title":"Hepatitis B virus infection","volume":"373","author":"YF Liaw","year":"2009","journal-title":"Lancet"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Gane EJ, Chan HL, Choudhuri G, Suh DJ, Chutaputti A, <etal>et al<\/etal>.. (2010) Treatment of decompensated HBV-cirrhosis: results from 2-years randomized trial with telbivudine or lamivudine [Abstract]. J Hepatol (Suppl. 1): S4.","DOI":"10.1016\/S0168-8278(10)60009-8"},{"key":"ref27","unstructured":"Gane EJ, Deray G, Piratvisuth T, Chan HL, Zeuzem S, <etal>et al<\/etal>.. (2011) Renal function is improved for Chronic Hepatitis B (CHB) patients treated with telbivudine [Abstract]. Hepatol (Suppl. 1): 1044A-1045A."},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"van B\u00f6mmel F, de Man R, Ferenci P, Bronowiki JP, F\u00fcl\u00f6p B, <etal>et al<\/etal>.. (2009) Long-term follow-up evaluation of the efficacy and safety of tenofovir disoproxil fumarate (TDF) in a European multicenter (nucleos(t)ide experienced) hepatitis B virus HBV-infected cohort. 60th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA, USA; Oct 30 - Nov 3, 2009 [Abstract 221]. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.hivandhepatitis.com\/2009icr\/aasld\/posters\/vanBommel.ppt\" xlink:type=\"simple\">http:\/\/www.hivandhepatitis.com\/2009icr\/aasld\/posters\/vanBommel.ppt<\/ext-link>. Accessed 2012 Jul 31.","DOI":"10.1055\/s-0030-1264032"},{"key":"ref29","first-page":"529A","article-title":"Risk of renal toxicity with tenofovir DF (TFD) for chronic hepatitis B (CHB) [Abstract]","volume":"52","author":"RG Gish","year":"2010","journal-title":"Hepatol"},{"key":"ref30","first-page":"1235","article-title":"Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B. J Hepatol","volume":"55","author":"S Mauss","year":"2011"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0054279","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T02:13:48Z","timestamp":1688004828000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0054279"}},"subtitle":[],"editor":[{"given":"Javier R.","family":"Lama","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,2,4]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2013,2,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0054279","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717985040.793472617","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,4]]}}}